Abatacept News and Research

RSS
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy.
Study Provides More Treatment Options for Severe COVID-19

Study Provides More Treatment Options for Severe COVID-19

Immune cell biomarker may help identify patients at risk for graft-versus-host disease

Immune cell biomarker may help identify patients at risk for graft-versus-host disease

Newly discovered biomarkers predict response to immunotherapy in Type 1 diabetes

Newly discovered biomarkers predict response to immunotherapy in Type 1 diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.